REGENEREX PHARMA, INC — Operating Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/dd0a5db2-d5ca-4119-b35f-24d15fa47965/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-1.8M | 2024-04-01 – 2025-03-31 | evidence 0001472375-26-000211 |
| FY 2023 | $-3.5M | 2023-04-01 – 2024-03-31 | evidence 0001472375-24-000045 |
| FY 2022 | $-96.2k | 2022-04-01 – 2023-03-31 | evidence 0001472375-23-000090 |
| FY 2021 | $-126.3k | 2021-04-01 – 2022-03-31 | evidence 0001472375-22-000055 |
| FY 2020 | $-43.4k | 2020-04-01 – 2021-03-31 | evidence 0001472375-22-000055 |
| FY 2019 | $-77.0k | 2019-04-01 – 2020-03-31 | evidence 0001472375-20-000033 |
| FY 2018 | $-91.7k | 2018-04-01 – 2019-03-31 | evidence 0001472375-19-000028 |
| FY 2017 | $-49.5k | 2017-04-01 – 2018-03-31 | evidence 0001472375-18-000067 |
| FY 2016 | $-2.6k | 2016-04-01 – 2017-03-31 | evidence 0001472375-18-000067 |
| FY 2011 | $-53.6k | 2010-06-26 – 2011-08-31 | evidence 0001072588-11-000208 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).